MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymgmr.2019.100564

Медицинская библиотека · Molecular genetics and metabolism reports · 2020

Liver involvement in patients with Gaucher disease types I and III.

Starosta Rodrigo Tzovenos, Vairo Filippo Pinto E, Dornelles Alícia Dorneles, Basgalupp Suélen Porto, Siebert Marina, Pedroso Maria Lúcia Alves, Cerski Carlos Thadeu Schmidt, Álvares-da-Silva Mário Reis, Schwartz Ida Vanessa Doederlein

СтатьяПеревод в очереди

Аннотация

BACKGROUND & AIMS: Gaucher disease (GD) is a multisystemic disease. Liver involvement in GD is not well characterised and ranges from hepatomegaly to cirrhosis and hepatocellular carcinoma. We aim to describe, and assess the effect of treatment, on the hepatic phenotype of a cohort of patients with GD types I and II.

METHODS

Retrospective study based on the review of the medical files of the Gaucher Reference Centre of the Hospital de Clínicas de Porto Alegre, Brazil. Data from all GD types I and III patients seen at the centre since 2003 were analysed. Variables were compared as pre- ("baseline") and post-treatment ("follow-up").

RESULTS

Forty-two patients (types I: 39, III: 3; female: 22; median age: 35 y; enzyme replacement therapy: 37; substrate reduction therapy: 2; non-treated: 3; median time on treatment-MTT: 124 months) were included. Liver enzyme abnormalities, hepatomegaly, and steatosis at baseline were seen in 19/28 (68%), 28/42 (67%), and 3/38 patients (8%), respectively; at follow-up, 21/38 (55%), 15/38 (39%) and 15/38 (39%). MRI iron quantification showed overload in 7/8 patients (treated: 7; MTT: 55 months), being severe in 2/7 (treated: 2/2; MTT: 44.5 months). Eight patients had liver biopsy (treated: 6; MTT: 58 months), with fibrosis in 3 (treated: 1; time on treatment: 108 months) and steatohepatitis in 2 (treated: 2; time on treatment: 69 and 185 months). One patient developed hepatocellular carcinoma.

CONCLUSIONS

GD is a heterogeneous disease that causes different patterns of liver damage even during treatment. Although treatment improves the hepatocellular damage, it is associated with an increased rate of steatosis. This study highlights the importance of a follow-up of liver integrity in these patients.

Для цитирования: Starosta Rodrigo Tzovenos, Vairo Filippo Pinto E, Dornelles Alícia Dorneles, Basgalupp Suélen Porto, Siebert Marina, Pedroso Maria Lúcia Alves, Cerski Carlos Thadeu Schmidt, Álvares-da-Silva Mário Reis, Schwartz Ida Vanessa Doederlein. Liver involvement in patients with Gaucher disease types I and III.. Molecular genetics and metabolism reports. 2020. DOI: 10.1016/j.ymgmr.2019.100564.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.